Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients

  1. Caballero-Velázquez, T.
  2. López-Corral, L.
  3. Encinas, C.
  4. Castilla-Llorente, C.
  5. Martino, R.
  6. Rosiñol, L.
  7. Sampol, A.
  8. Caballero, D.
  9. Serrano, D.
  10. Heras, I.
  11. San Miguel, J.
  12. Pérez-Simón, J.A.
Journal:
British Journal of Haematology

ISSN: 0007-1048 1365-2141

Year of publication: 2013

Volume: 162

Issue: 4

Pages: 474-482

Type: Article

DOI: 10.1111/BJH.12410 GOOGLE SCHOLAR